Karl Arnberg is Head of unit at one of the Value Based Pricing units at the governmental authority, the Dental and Pharmaceutical Benefits Agency (TLV), Sweden. He has a degree in economics and political science from the University of Lund.

Karl has been involved in decision making at the TLV since 2004. At TLV he has been working with most aspects of health economic assessment, from the assessment of specific drugs to strategic questions in the application of value based pricing. At his current position he is heading a unit specializing in therapeutic areas such as rheumatology, respiratory, and neurology.

Sune has been working in the pharmaceutical area for 10 years and in business intelligence for 15 years. Originally educated in finance and administration within the oil industry. Since 2007 he has been working at Amgros -  the pharmaceutical organization of the Danish regions. He is part of the team that designed the Danish model for health technology assessments regarding hospital pharmaceuticals.

Dorthe Bartels is a strategic advisor in pharmaceuticals for Amgros (Amgros national procurement organization for Denmark).  Dorthe is also a negotiator for new medicines and responsible for the national biosimilar task force, who supports the regions and medicine councils in handlings and implementations of biosimilars in Denmark.

Dorthe has a MSc in Pharmacy and MSc in business and has extensive experience in the pharmaceutical industry and has been the head of procurement, tendering and logistics in Amgros for last  8 years. 

Jan Liliemark is professor in pharmacotherapy and program manager at the Swedish Council of Health Technology Assessment (SBU). The SBU delivers HTA-rapports on various methods within the health area, comprehensive rapports on a full subject area, focussed alert rapports on new methods, commentary rapports on other agencies full rapports and finally, a service for decision makers delivering rapid focussed rapports on specific questions. Jan was also project manager within the Swedish Association for Local Authorities and Regions (SALAR) for managed introduction of new medicines in Sweden 2012-2014.

Jan Liliemark has a background in clinical practise, mainly clinical haematology and oncology between 1981 - 1998. Jan Liliemark has also a research background since 1978 with more than 100 published scientific papers. After 3-4 years as medical affairs manager at Schering-Plough, Nordic Biotech, he worked as scientific director at the Medical Product Agency (MPA) in Sweden between 2001 - 2010.

Sofie Alverlind is part of the Department of Health Care at the Swedish Association of Local Authorities and Regions (SALAR), where her main role is supporting the Swedish county councils on questions concerning new drugs. She is the coordinator of the New Therapies (NT) Council, an expert committee giving the county councils recommendations on new drugs and has lead a pilot project on preparing the Swedish county councils for managed introduction of medical devices. Sofie has an MSc in Pharmacy and has a long experience of drug development as a Clinical Pharmacology Scientist.

Robert is heading the Swedish Pharmaceutical Insurance since 2016. He holds a Master degree from the University of Linköping, Sweden and have also studied at Sussex University, GB, University of Wisconsin, US and Harvard Business School, US. Robert has many years of experience from the medical device and the pharmaceutical industry, among other experiences as head of Nordic Medical Division at Becton Dickinson and head of Nordic Region for Baxter International. He has previously also been the chairmen of LIF (the research based industry association in Sweden) and is presently member of the Advisory Council of Läkemedelsverket (Swedish Medical Product Agency).

Morten Elbæk Petersen has been the CEO of the Danish eHealth portal, sundhed.dk, since it was founded in 2003. He has more than 20 years of management experience in public administration with a primary focus on implementing eHealth, quality development, prevention and patient empowerment.  The Danish eHealth portal pioneers open access to medical records, and is in this regard unique worldwide. Morten Elbæk Petersen holds a Master’s degree in Economics and Social Science from the University of Odense. He also serves as an external lecturer and examiner for Public Health IT Masters programmes at Danish universities. In 2015, he received HIMSS Europe eHealth Leadership Award.

Priit Tohver is a junior doctor and the advisor to the Deputy Secretary General for E-Services and Innovation at the Ministry of Social Affairs in Estonia, overseeing the digital transformation and innovation of social security in Estonia, including health, labour and social matters. He has previously served as an advisor to the Estonian Mission in Geneva on diplomatic matters related to health, development and trade, covering organizations such as WHO, UNCTAD and WTO during the Estonian presidency of the Council of the EU. He has several years of experience representing Estonia to high level health meetings such as the World Health Assembly, the WHO Executive Board and the European Regional Committee. Priit has six years of experience as a civil society and global health activist, having also served as the Regional Director for Europe at the International Federation of Medical Students’ Associations (IFMSA).

Dr. Steinar Madsen is medical director at the Norwegian Medicines Agency. He has been working with generic substitution since it was introduced in Norway in 2001 and with biosimilars since 2006. He is member and previously chairman of the committee for generic substitution at the Agency. Dr. Madsen is also engaged in the drug information service, with a special interest in the safe and cost-effective use of drugs. He is a specialist in internal medicine and cardiology and works part time as a consultant in cardiology.

Elina Asola joined Pharmaceuticals Pricing Board in January 2004. She is responsible for developing and coordinating the operations of the secretariat of Pharmaceuticals Pricing Board. In addition she acts as a presenting officer in the meetings of Pharmaceutical Pricing Board. She presents mainly applications on new active compounds and extensions of reimbursement. She is also representing Pharmaceuticals Pricing Board in MEDEV (Medicine Evaluation Committee) which is an informal cooperation between EU member states.

She has graduated from University of Helsinki with a Master’s degree in Pharmacy (Pharmacology). Prior to joining Pharmaceuticals Pricing Board, Elina worked for a couple of years as Research Manager for small biotech company.

Göran Larsson has a Ph.D. in medical biophysics from Umea University. After his Ph.D. Göran joined University of Cambridge, UK for a three year Post.Doc period. In 2004 he returned to Umea University where he worked as a university teacher and researcher until 2012 when he moved to Östersund for his current position as Director of Research and Education in Region Jämtland Härjedalen. In 2014 he become Professor in medical biophysics. Göran Larsson is interested in eHealth/mHealth solutions and is responsible for innovation processes related to digitalization of healthcare in his organization.

Jonas joined LIF in September 2015. He graduated from University of Stockholm in 2003 with the equivalent of a master degree in Media and Communication Science. Prior to LIF, Jonas has work as a political advisor at the Swedish Government and at the Swedish Parliament. He has also held various positions at GSK in Sweden.

Madlaina has over 10 years of experience in health economics and outcome research from different global and local positions in the pharmaceutical industry as well as from academia. She joined Novartis five years ago driving the utilization of register data in Sweden and today, Madlaina is building up and leading a new Nordic RWE organization at Novartis.

Madlaina has a master degree in pharmaceutical sciences and completed her PhD within the field of clinical epidemiology and health economics.

Rebecca Currie is Market Access and Pricing Manager at Lundbeck Pharma A/S, the Nordic and Baltics business cluster of H. Lundbeck A/S. Prior to Lundbeck, Rebecca worked for many years at the Danish pharmaceutical company Novo Nordisk A/S, working in a number of global positions across the value chain, including Market Access and Public Affairs. She has a background in International Business, Marketing Management, and Modern Languages, from the UK, Germany and Denmark.

Original educated within biochemistry in Denmark, Trine have spend last 19 years in pharma industry. Work experience is spread on commercial, external affair and market access and selling excellence, with the last 2,5 years being in a European role for GSK, based in London HQ.

Trine have experience with companies in pharma  and med-tech, locally and globally (Ferring, Coloplast, GSK)  as well as following a graduate diplome in Copenhagen Business School in global supply chain management.

Current responsibilities is Region Europe Market Access for the GSK brands with specific focus  on Respiratory disease management and HIV, as well as rare disease management

Nicholas joined Bristol-Myers Squibb in 2013 as Market Access Lead, Sweden. During his tenure with BMS, Nicholas has led the pricing negotiations with Swedish payers in more than 25 different cases focusing on a broad range of therapeutic areas such as immune-oncology, hepatitis C and atrial fibrillation. He has also led cross-functional European projects within Market Access, Public Policy, Pricing and Social Media. A few selected projects include global pricing projects for novel BMS drugs as well as Horizont (a paper magazine and webzine focusing on Swedish healthcare, the evolvement of life sciences and the people involved). Nico graduated from the Gothenburg School of Economics & Business with a Master of Science degree in 2000. Prior to joining Bristol-Myers Squibb, Nicholas worked for more than ten years at AstraZeneca and Boehringer-Ingelheim in different roles within sales, marketing, clinical operations and market access. In 2012, he was awarded the pharma profile of the year in Sweden.

Christoffer joined Bristol-Myers Squibb in January 2011 as an Associate Director of Pricing, Reimbursement & HEOR. During his tenure with BMS, Christoffer has worked in 14 markets, held European roles within Market Access & HEOR and participated in more than 25 different reimbursement submissions across Europe, mainly focusing on Oncology. Christoffer graduated from the Stockholm School of Economics with a Master of Science degree in Business and Economics in 2002. He subsequently completed his Licentiate’s research degree in Industrial Marketing at the Stockholm School of Economics in 2007. Prior to joining Bristol-Myers Squibb, Christoffer worked for four years as Value Demonstration Lead at Roche and before that as a Health Economist at Schering-Plough.

Kristina has almost 10 years of experience in RWE, from academia, consultancy, and the pharma industry. She joined Lilly in 2014 and has since then held both global and local roles. Since about a year back, Kristina is leading the RWE strategy development and implementation of RWE studies in the Nordic region. Prior to joining Lilly, Kristina worked for Evidera in their RWE and epidemiology team. Kristina has a master degree in health economics (HE) and a PhD in HE/outcomes research from the University of Granada, Spain. 

Mr Gårdebäck program director for the Swedish National Strategic Innovation program Medtech4Health which focus on financing of innovative projects and strategic collaborations, nationally and internationally within the medtech area.  By acting as catalyst, Medtech4Health seek to encourage the increased implementation of medical technical solutions in healthcare, make healthcare more effective, and strengthen the Swedish medtech industry. This is done through awarding funding to different projects, through strategic investments, and by lobbying at different levels both inside and outside Sweden. The program is governemnet founded through the Swedish Innovation Agency VINNOVA and have a financing budget around 6 Million Euro / year.

Mr Gårdebäck has more than 25 years of experience in global international medtech companies like Siemens, Elekta, GE Medical systems and Medtronic.  The last two Mr Gårdebäck held the position as CEO for the business in Sweden.  He is also board member in several companies and has a technical degree as Master of Science in Physics from KTH, the Royal Institute of Technology. In addition to general management positions Mr Gårdebäck have experience working in R&D departments as well as project management and marketing & sales positions including tendering and healthpolicy related activities.

Martin has worked in the field of medical technology and pharmaceuticals for over 20 years in various companies like Pfizer, J&J, Boston Scientific and in leading roles within Marketing, Sales and Health Economics. He has an educational background as an Economist and Registered Nurse. Today, Martin is Global Senior Director at Mölnlycke Healthcare and has a part-time assignment in the Nordic project “Nordic Medtech Growth2” funded by the Nordic Council of Ministers via Nordic Innovation. He´s also a member of Nordic health-economic expert committees in Swedish Medtech, Medtek Norway and Medico Industrien (Denmark) and an active member of the European project "MEAT" operated by Medtech Europe.

Henrik has a Master of Public Administration from Copenhagen Business School as well as a medical degree and a PhD from the University of Copenhagen Henrik has extensive experience within health, research and innovation. He has worked within both the private and public sectors at home and abroad in various leadership positions. In his current role as Chief Medical Officer, IBM Nordic, he works with digital transformation by developing and applying innovative technology and methodology within the public healthcare sector and the life science industry.

More than 10 years of top performance in multi-brand marketing and product portfolio responsibility spread across various companies, brands and product categories in the Nordic countries and Estonia. With primary focus on BtB and BtBtC and some BtC communication.

I find It Important to help our customers maintain both the brand value, positioning and USP in all parts of the value chain.

I have a unique background from both retail and sales that has given me extensive expertise and understanding or the full value chain. Making me able to understand all my customer’ and sales teams needs and therefore the opportunity to adapt my work to align with their demands, requests and future needs.

I am fascinated and passion about developing the right compelling communication, that can link all the strategies from marketing, product and sales together, to provide insight to consumer, increase sales and market shares, and help growing the company through a strong sales force.

Several years of senior experience in management and retention of my marketing strategies across borders in a complex matrix organization with responsibility for e.g. product specialists, trade marketers and the different countries' focus areas and strategies.

Dr Svendsen is project leader for the project ‘Innovation accelerators’, a strategic project within Medtech4health, run by Swedish Medtech. Swedish Medtech is the Association for Medical Technology in Sweden and has approximately 180-member companies. The diversity of the medical technology industry is reflected in the wide selection of products offered by their member companies.
In her last two previous positions Dr Svendsen has been working with innovation policy at the Ministry of Enterprise and Innovation as a programme manager for the programme ‘Challenge Driven Innovation’ at Vinnova, Sweden´s innovation agency. She has a PhD in material processing from KTH, the Royal Institute of Technology. She also has experience with working in a start-up company.

COO and deputy CEO of Brighter AB (publ) – A human innovation company, servicifying and democratizing healthcare. Experienced impact investor and executive. Investor in Brighter since 2012, Board member 2012-2014. Extensive international experience in starting and developing companies (Swifler.com, Casa Cor and others), in addition to heading up ABB Equity Ventures’ establishment and investment in Brazil from 1996 to 2002. On a personal level, Henrik Norström is dedicated to making an impact on peoples' lives. It took a while to realize where the energy was to be funneled, but when Brighter appeared as an opportunity, this was clear. Current non-executive assignments: Chairman of Swifler Holding AB and Adstring AB. Advisor to Allone AB and Haaartland Technologies AB as well as election committee member of Brighter AB (publ) and Camanio Care AB (publ)

Steen is educated as a medical oncologist and has been working as DCE at Herlev and Gentofte Hospital during the last 6 years. Furthermore, he has been working with assessment and recommendation of new drugs for more than 20 years. He is currently scientific adviser for the European Medicines Agency (SAG Oncology) and co-chairman of the Danish Medicines Council.

Elisabeth Eklund is a partner with the Swedish law firm Delphi. Her main areas of practice include competition law and regulatory issues (including pricing and reimbursement, Health Care Compliance and CE-marking) and advertising law with particular focus on life sciences. Elisabeth has been working with pharmaceutical and medical device companies, both as regards pro-active measures, contacts with authorities and court proceedings for over fifteen years and is recognized by several international ranking institutes as a leading individual in this field in Sweden. Elisabeth holds a law degree from Stockholm University and a LL.M. in European and international Law from the European University Institute in Florence. Prior to joining Delphi in 2005 she worked with the competition law team of Linklaters and served as a clerk at the Stockholm County Administrative Court.

Until recently Finn was chairman of the Executive Committee, European Network for Health Technology Assessment, EUnetHTA, and Director of it’s Coordinating Secretariat, National Board of Health, Denmark. Adjunct professor in health services research and health technology assessment at University of Southern Denmark from 1999. Formerly Director of Danish Centre for Health Technology Assessment (DACEHTA), National Board of Health, Denmark 1997 - 2009. University graduate in medicine. PhD in Epidemiology. Specialty in General Practice and in Public Health. International projects in health services research, epidemiology, health technology assessment, and clinical practice guidelines since the 1980’s. Chairman International Network of Agencies for Health Technology Assessment (INAHTA) 2003 -06. Project Leader of EUnetHTA, 2006-08 (www.eunethta.net). Editor of Health Technology Assessment Handbook (English, translated), 2007 and chief editor of three peer reviewed publication series from DACEHTA 1998 - 2009. Member, UK NHS HTA Programme Advisory Group since 2005. Chair, Scientific Council, Ludwig Bolzmann Institute of HTA, Austria since 2007

Mattias is leading market access activities at Synergus. He has over 20 years of experience from the Medical Device Industry. Mattias started his career within quality and regulatory and has held several positions within production, quality, logistics and R&D in a global medical device corporation specialized in intensive care. During the years, Mattias also developed a very unique and extensive reimbursement and market access knowledge and is today combining his regulatory and business development insights when consulting medical device companies worldwide on how to develop their reimbursement and regulatory strategies. He has considerable experience in development of Pan-European reimbursement strategies for medical device companies.

Dr Tim Spelman is a biostatistician of 16 years’ experience having worked with a variety of national and international research organisations including the Australian Bureau of Statistics, Melbourne Brain Centre, the Burnet Institute, Monash University’s Department of Epidemiology and Preventive Medicine, the Victorian Infectious Diseases Service, the Peter Doherty Institute for Infection and Immunology, the Department of Health the United Nations Programme on HIV/AIDS, Flinders University  and Deakin University among others. He has over 135 publications in infectious diseases, immunology, multiple sclerosis, neurology, population health, epidemiology and virology. He is currently senior advising statistician to the Lancet and senior advising statistician to the Economics Sub-Committee of the Pharmaceutical Benefits Advisory Committee.

He is currently a member of the editorial board of the Journal of the International AIDS Society and the current guest Lead Editor for the Biomed International Research Journal. He is also currently a member of the international Tysabri Observation Programme steering committee and a member of the Data Management Sub-Committee for the Big MS Data Network International Collaborative of Multiple Sclerosis data registries. He is currently a member of the Data and Safety Monitoring Committee (DSMC) of the NICE-GUT randomised clinical trial of nitazoxanide for treating Aboriginal children hospitalised for gastroenteritis in the Northern Territory as well as working previously as a clinical trial statistician. He has presented research at many international conferences and workshops and run statistical training courses for researchers and clinicians in Australia, Europe, the United States, South-East Asia and Southern Africa and has collaborated extensively with research groups globally including the UN, WHO, MSF, the Karolinska Institute, Oxford and Harvard. He has also extensive clinical experience, and currently practices as a General Practitioner. He also has extensive management experience, supervising both junior statisticians and epidemiologists in addition to trainee clinicians. 

Fredrik Östman has degrees in mathematics and computing science and currently works as a developer for software in multivariate analysis in Umeå. As a Stage 4 Melanoma patient since 2014, he is alive thanks to an innovative therapy that he could access via a compassionate use program in 2015 and has therefore a very acute perspective on the true value of medical innovation, what 'timely access' really means and the risk a patient is willing to accept in order to stay alive.

Fredrik is an avid cross-country skier and mountain climber and board member of the Swedish Melanoma association Melanomföreningen.